Browse by author
Lookup NU author(s): Dr Roshan MascarenhasORCiD
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
© The Author(s) 2025.Background: In cervical cancer (CC), Double C2 Like Domain Beta (DOC2B) functions as a metastatic suppressor. The present study aims to determine whether ectopic expression of DOC2B causes global metabolomic changes in extracellular vesicles (EVs) and corresponds with its tumor suppressive properties. Methods: Using a retroviral method, we first ectopically expressed DOC2B in SiHa cells, which do not normally express DOC2B. Results: We observed that ectopically expressed DOC2B significantly altered the global metabolite profile of EVs. Metabolomics identified significant enrichment of palmitoylcarnitine (PC) in EVs upon ectopic expression of DOC2B. We identified that SiHa and HeLa cells exhibited greater cytotoxicity to PC than gingival fibroblast, HaCaT, Cal27, and MCF7. PC treatment reduced the growth, proliferation, and migration of SiHa and HeLa cells, via increasing apoptosis and decreasing S-Phase cells. PC treatment resulted in morphological alterations, decreased length and number of filopodia, and expression of proteins related to cell cycle progression, proliferation, and the epithelial-to-mesenchymal transition. Further, PC treatment caused mitochondrial morphological changes, increased mitochondrial membrane potential, and decreased mtDNA content. The decreased GSH activity, glucose consumption rate, and lactate production upon PC treatment suggest that PC can induce metabolic reprogramming in CC cells. Increased oxidative stress, calcium overload, lipid droplet accumulation, mitochondrial lipotoxicity, and mitophagy suggest that PC can cause mitochondrial dysfunction. N-acetyl cysteine (NAC) treatment reversed the cytotoxic effect of PC, via decreasing lipid peroxidation rate and increasing GSH activity. PC treatment enhanced the cytotoxic effect of cisplatin in CC. Conclusion: DOC2B restoration or the use of PC may be employed as a novel therapeutic approach for CC.
Author(s): Eswaran S, Mascarenhas R, Kabekkodu SP
Publication type: Article
Publication status: Published
Journal: Cell Communication and Signaling
Year: 2025
Volume: 23
Issue: 1
Online publication date: 03/05/2025
Acceptance date: 25/04/2025
Date deposited: 13/05/2025
ISSN (electronic): 1478-811X
Publisher: BioMed Central Ltd
URL: https://doi.org/10.1186/s12964-025-02218-8
DOI: 10.1186/s12964-025-02218-8
Data Access Statement: No datasets were generated or analysed during the current study.
Altmetrics provided by Altmetric
